Jennifer Landrette, APRN
Psychiatric/Mental Health · Washington, DCNPI 1609193671
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,109, more than ten times the $46 reported in 2021.
Across 70 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$309
- Teva Pharmaceuticals USA, Inc.$287
- Alkermes, Inc.$254
- Johnson & Johnson$195
- Neurocrine Biosciences, Inc.$158
- AbbVie$126
- plus $219 from 5 others
What the payments were for
- Food & beverage$1,42292%
- Education$1278%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 18 | $309 |
| Teva Pharmaceuticals USA, Inc. | 10 | $287 |
| Alkermes, Inc. | 16 | $254 |
| Johnson & Johnson | 5 | $195 |
| Neurocrine Biosciences, Inc. | 5 | $158 |
| AbbVie | 7 | $126 |
| Vanda Pharmaceuticals Inc. | 3 | $90 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Lundbeck LLC | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $28 |
| Indivior Inc. | 1 | $16 |
How this compares
$1,548 in reported general payments places this provider in the 80th percentile of 137 psychiatric/mental health providers in District of Columbia.
See all psychiatric/mental health providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 144 | $466,438 |
| Abilify MaintenaAripiprazole | 58 | $174,615 |
| AristadaAripiprazole Lauroxil | 48 | $172,929 |
| IngrezzaValbenazine Tosylate | 17 | $148,539 |
| VraylarCariprazine Hcl | 30 | $43,668 |
| Lurasidone Hcl | 56 | $17,097 |
| Haloperidol Decanoate | 123 | $6,760 |
| Olanzapine | 331 | $6,115 |
| Divalproex Sodium ErDivalproex Sodium | 134 | $5,981 |
| Clozapine | 34 | $5,209 |
| Ziprasidone Hcl | 72 | $5,087 |
| Aripiprazole | 158 | $4,484 |
| Divalproex Sodium | 140 | $4,095 |
| Fluphenazine Decanoate | 30 | $3,990 |
| Chlorpromazine Hcl | 31 | $2,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $195 | $466,438144 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $47 | $174,61558 claims |
| Alkermes, Inc.Aristada | $254 | $172,92948 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $158 | $148,53917 claims |
| AbbVieVraylar | $126 | $43,66830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 137 psychiatric/mental health providers in District of Columbia.
Other psychiatric/mental health in Washington
- Erin WalczykowskiWashington$349K
- Caroline BonuWashington$16K
- Miriam EzenwakaWashington$6K
- Orin GreeneWashington$4K
- Hope AchoronyeWashington$4K
- Samantha HyltonWashington$4K
- Nkechi OnwucheWashington$4K
- Emmanuel Kamdem SangoWashington$4K
- Arithia HardenWashington$4K
- Zion DestaWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.